GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (NAS:GWPH) » Definitions » Return-on-Tangible-Asset

GW Pharmaceuticals (GW Pharmaceuticals) Return-on-Tangible-Asset : -8.51% (As of Mar. 2021)


View and export this data going back to 2013. Start your Free Trial

What is GW Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. GW Pharmaceuticals's annualized Net Income for the quarter that ended in Mar. 2021 was $-78.7 Mil. GW Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2021 was $924.6 Mil. Therefore, GW Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2021 was -8.51%.

The historical rank and industry rank for GW Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

GWPH' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -64.2   Med: -11.05   Max: 8.72
Current: -7.85

During the past 13 years, GW Pharmaceuticals's highest Return-on-Tangible-Asset was 8.72%. The lowest was -64.20%. And the median was -11.05%.

GWPH's Return-on-Tangible-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.83 vs GWPH: -7.85

GW Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for GW Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GW Pharmaceuticals Return-on-Tangible-Asset Chart

GW Pharmaceuticals Annual Data
Trend Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.09 -33.46 -64.20 -1.33 -6.45

GW Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.71 -4.16 -5.55 -12.78 -8.51

Competitive Comparison of GW Pharmaceuticals's Return-on-Tangible-Asset

For the Drug Manufacturers - General subindustry, GW Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GW Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GW Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where GW Pharmaceuticals's Return-on-Tangible-Asset falls into.



GW Pharmaceuticals Return-on-Tangible-Asset Calculation

GW Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2020 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=-58.128/( (875.29+926.987)/ 2 )
=-58.128/901.1385
=-6.45 %

GW Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2021 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2021 )  (Q: Dec. 2020 )(Q: Mar. 2021 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2021 )  (Q: Dec. 2020 )(Q: Mar. 2021 )
=-78.708/( (926.987+922.113)/ 2 )
=-78.708/924.55
=-8.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2021) net income data.


GW Pharmaceuticals  (NAS:GWPH) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


GW Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of GW Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


GW Pharmaceuticals (GW Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ
GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.
Executives
Douglas B. Snyder officer: Chief Legal Officer SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB249BZ
Volker Knappertz officer: Chief Medical Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Cabot Brown director SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Adam D. George officer: Secretary SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Guy Geoffrey W Dr director, officer: Executive Chairman ETHICAL HOLDINGS PLC CORPUS CHRISTI HOUSE 9 WEST STREET GODMANCHESTER CAMBRIDGESHIRE PE18 A1
Christopher J. Tovey officer: Chief Operating Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Justin D. Gover director, officer: Chief Executive Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
James Noble director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Alicia Secor director 33 HAYDEN AVE., LEXINGTON MA 02421
Darren S Cline officer: U.S. Chief Commercial Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
William A. Waldegrave director SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Julian S Gangolli officer: President, North America 4955 BASELINE AVENUE, SANTA YNEZ CA 93460